SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Dorgan J. F.)
 

Search: WFRF:(Dorgan J. F.) > Anti-Mullerian horm...

Anti-Mullerian hormone and risk of invasive serous ovarian cancer

Schock, Helena, 1984- (author)
Umeå universitet,Patologi,Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer
Lundin, Eva, 1955- (author)
Umeå universitet,Patologi
Vääräsmäki, M. (author)
Oulu, Finland
show more...
Grankvist, Kjell, 1954- (author)
Umeå universitet,Klinisk kemi
Fry, A. (author)
London, UK
Dorgan, J. F. (author)
Baltimore, MD, USA
Pukkala, E. (author)
Helsinki, Finland; Tampere, Finland
Lehtinen, M. (author)
Tampere, Finland
Surcel, H. M. (author)
Oulu, Finland
Lukanova, Annekatrin, 1966- (author)
Umeå universitet,Patologi,Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer
show less...
 (creator_code:org_t)
2014-02-22
2014
English.
In: Cancer Causes and Control. - : Springer. - 0957-5243 .- 1573-7225. ; 25:5, s. 583-589
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Epithelial ovarian cancers either arise directly from Mullerian-type epithelium or acquire Mullerian characteristics in the course of neoplastic transformation. The anti-Mullerian hormone (AMH) causes regression of Mullerian structures during fetal development in males and has been shown to inhibit the growth of epithelial ovarian cancer. Therefore, we hypothesized that pre-diagnostic serum concentrations of AMH are inversely associated with risk of invasive serous ovarian cancer. A case-control study (107 cases, 208 controls) was nested within the population-based Finnish Maternity Cohort (1986-2007). The sample donated during the first trimester of the last pregnancy preceding cancer diagnosis of the case subjects was selected for the study. For each case, two controls, matched on age and date at sampling, as well as parity at sampling and at cancer diagnosis were selected. AMH was measured by a second-generation AMH ELISA. Conditional logistic regression was used to compute odds ratios (OR) and 95 % confidence intervals (CI) for invasive serous ovarian cancer associated with AMH concentrations. Overall AMH concentrations were not associated with risk of invasive serous ovarian cancer (OR 0.93; 95 % CI 0.49-1.77 for top vs. bottom tertile, P (trend) = 0.83). In women older than the median age at sampling (32.7 years), a doubling of AMH was associated with decreased risk (OR 0.69; 95 % CI 0.49-0.96), whereas an increased risk (OR 1.64; 95 % CI 1.06-2.54) was observed in younger women, P (homogeneity) = 0.002. In this first prospective investigation, risk of invasive serous ovarian cancer was not associated with pre-diagnostic AMH concentrations overall; however, the association may depend on age at AMH measurement.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Anti-Mullerian hormone
Ovarian neoplasms
Pregnancy
Case-control studies
Prospective studies

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view